Preimplantation Genetic Testing (PGT) may be worth considering for some IVF patients, particularly when there is a known genetic condition or a specific reproductive reason for testing. However, PGT is not necessary for everyone and does not guarantee pregnancy or a healthy baby. Understanding its benefits, limitations, and costs can help you decide whether it fits your individual fertility treatment plan.
At Fertility & Wellbeing Centre in Dubai, patients can discuss PGT as part of an individualized IVF treatment approach.
Preimplantation Genetic Testing is a specialized laboratory procedure performed during IVF.
After eggs are fertilized and embryos develop in the laboratory, an embryo may undergo biopsy at the blastocyst stage. A small sample of cells is analyzed for the specific genetic or chromosomal characteristic being investigated.
There are several types of PGT, including:
Used to assess chromosome number, specifically aneuploidy.
Used to test for a specific monogenic or single-gene disorder.
Used to assess certain structural chromosome rearrangements.
Each test has a different purpose, so the first question should not simply be “Should I have PGT?”
A better question is:
“Would PGT provide useful information for my particular IVF situation?”
No.
PGT is not a routine requirement for every IVF cycle.
The potential value of PGT depends on factors such as:
For example, a couple carrying a known genetic condition may have a very different reason for considering PGT-M than an IVF patient considering PGT-A.
This is why PGT decisions should be individualized.
One of the biggest potential benefits of PGT is that it provides information that may not be available through routine embryo assessment alone.
Embryologists can assess embryo development and appearance, but genetic testing can provide additional information about the specific genetic or chromosomal feature being tested.
This can help inform discussions about embryo transfer.
For couples who have a known risk of passing on a particular single-gene condition, PGT-M can be an important reproductive option.
PGT-M is specifically designed around the genetic condition being investigated.
It may allow affected embryos to be identified before embryo transfer.
This can be particularly meaningful for couples who have previously experienced a pregnancy or child affected by a genetic disorder.
Some individuals carry structural chromosome rearrangements without experiencing obvious health problems themselves.
However, these rearrangements can affect reproductive outcomes.
PGT-SR can be considered in selected circumstances to provide information about embryos in relation to the known structural chromosome rearrangement.
PGT-A examines embryos for abnormalities in chromosome number.
Chromosomal abnormalities are an important consideration in human reproduction, particularly because the likelihood of aneuploid embryos changes with maternal age.
However, this does not mean that every older IVF patient automatically needs PGT-A.
The American Society for Reproductive Medicine notes that PGT-A has not been established as a universal screening test for all IVF patients.
This is where patients need to be particularly careful.
It would be inaccurate to say:
“PGT guarantees a higher IVF success rate.”
It does not.
PGT provides specific genetic information, but pregnancy depends on many factors.
These can include:
Therefore, PGT should not be marketed as a guarantee of IVF success.
Like every medical test, PGT has limitations.
A PGT result relates to the specific testing performed.
For example, PGT-A does not mean that an embryo has been screened for every genetic disease.
Similarly, PGT-M is designed around a particular monogenic condition rather than every possible genetic disorder.
Even an embryo with a favorable PGT result may not implant.
Embryo implantation involves complex biological processes that cannot be predicted by PGT alone.
This is extremely important.
A favorable PGT result does not eliminate every possible genetic, developmental or medical risk.
Prenatal screening and, where appropriate, diagnostic testing may still be recommended during pregnancy.
Patients sometimes assume that every egg collected during IVF will eventually become an embryo available for PGT.
That is not the case.
There may be attrition at multiple stages:
Eggs retrieved → mature eggs → fertilized eggs → developing embryos → blastocysts → biopsied embryos → testable embryos → embryos potentially suitable for transfer
Therefore, the number of eggs retrieved cannot be used to predict exactly how many embryos will ultimately be available for testing or transfer.
The cost of PGT in Dubai varies depending on several factors.
These may include:
For PGT-M, for example, additional laboratory preparation may sometimes be required because testing is designed around a specific genetic condition.
Therefore, patients should ask for a complete treatment estimate rather than looking only at the headline PGT price.
“Does the quoted PGT price include all laboratory and genetic-testing costs?”
This can help avoid unexpected expenses.
Instead of asking only:
“How much does PGT cost?”
consider asking:
“What clinical information will PGT provide, and how could that information affect my treatment decisions?”
For a couple with a known inherited condition, PGT-M may provide highly relevant reproductive information.
For another patient, the potential benefit may be less clear.
The value of testing therefore depends on the clinical context.
PGT may be discussed in situations such as:
A couple has a known risk of passing a specific single-gene disorder to their child.
One partner carries a relevant chromosome rearrangement.
A fertility specialist may discuss embryo genetic testing after considering previous reproductive outcomes and the patient’s overall situation.
PGT-A may be considered when chromosome information could potentially help with embryo selection, after discussing its benefits and limitations.
There may be situations where PGT offers limited practical value.
For example:
The decision should always be based on a realistic understanding of what the test can accomplish.
One reason patients consider PGT is to obtain additional information before embryo transfer.
However, genetic testing should be viewed as one part of embryo selection, not the only factor.
The fertility team may consider:
The final transfer strategy should therefore be individualized.
Age can be an important consideration, but it should not be the only factor.
The relationship between maternal age and embryo aneuploidy is well established, but the decision to perform PGT-A requires consideration of the complete clinical picture.
A fertility specialist may evaluate:
The question is not simply “Am I old enough for PGT-A?”
Instead:
“Would PGT-A provide meaningful information in my specific circumstances?”
| IVF Without PGT | IVF With PGT |
|---|---|
| Embryos are created through IVF | Embryos are created through IVF |
| Embryos are assessed through laboratory methods | Embryos may undergo biopsy and genetic analysis |
| No PGT-specific genetic information | Additional information about the tested genetic/chromosomal feature |
| May involve fresh or frozen transfer depending on the plan | Embryos are generally frozen while testing is completed |
| Lower testing complexity | Additional laboratory and testing steps |
| Suitable for many IVF patients | Appropriate only when the potential value justifies testing |
Before paying for PGT, consider asking your fertility specialist:
You should understand the specific clinical reason.
PGT-A, PGT-M and PGT-SR are not the same.
Ask your doctor to explain the scope of testing in simple terms.
Your clinic can explain how embryo numbers may affect the treatment pathway.
Ask about alternative treatment options.
Confirm laboratory, genetic counselling, testing, freezing and transfer costs.
In many circumstances, appropriate prenatal screening or diagnostic testing remains important.
At Almond Blossoms Fertility & Wellbeing Centre, patients can discuss PGT as part of a personalized IVF treatment plan.
The clinic’s PGT service includes:
The appropriate testing option depends on the individual’s reproductive history, genetic circumstances and treatment goals.
For more information, link this supporting blog to your main commercial service page:
PGT can be worth considering when the information it provides has a clear clinical purpose.
For couples with a known inherited genetic condition, PGT-M may offer valuable reproductive information. For people with certain structural chromosome rearrangements, PGT-SR may be relevant. In selected IVF situations, PGT-A may provide additional information about embryo chromosome status.
But PGT is not a guarantee of IVF success, and it is not automatically necessary for every patient.
The best decision is one based on your individual fertility history, genetic circumstances, number of embryos, treatment goals and a clear understanding of the test’s benefits and limitations.
If you are considering PGT in Dubai, speak with a qualified fertility specialist to determine whether genetic testing could be appropriate for your IVF journey.
It depends on the individual. PGT may provide valuable information in selected clinical situations, but the potential benefit should be weighed against its cost and limitations.
No. PGT cannot guarantee implantation, pregnancy or live birth.
The genetic testing is performed on embryo biopsy samples in the laboratory. Patients do not undergo a separate painful procedure to have the embryo cells tested.
There is no universal minimum number, but the number of embryos available can affect how useful testing is and whether an embryo may ultimately be available for transfer.
PGT-A can assess embryos for chromosome-number abnormalities involving chromosome 21, but it does not guarantee the absence of every genetic or medical condition. Prenatal testing remains important.
Not necessarily. PGT-A may be useful for selected patients, but it is not universally recommended for every IVF cycle.